These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
772 related articles for article (PubMed ID: 33449302)
1. Clinical Treatment Options in Scleroderma: Recommendations and Comprehensive Review. Zhao M; Wu J; Wu H; Sawalha AH; Lu Q Clin Rev Allergy Immunol; 2022 Apr; 62(2):273-291. PubMed ID: 33449302 [TBL] [Abstract][Full Text] [Related]
2. Emerging diagnostic and therapeutic challenges for skin fibrosis in systemic sclerosis. Abraham D; Lescoat A; Stratton R Mol Aspects Med; 2024 Apr; 96():101252. PubMed ID: 38325132 [TBL] [Abstract][Full Text] [Related]
3. New therapeutic strategies for systemic sclerosis--a critical analysis of the literature. Zandman-Goddard G; Tweezer-Zaks N; Shoenfeld Y Clin Dev Immunol; 2005 Sep; 12(3):165-73. PubMed ID: 16295521 [TBL] [Abstract][Full Text] [Related]
4. Strategy for treatment of fibrosis in systemic sclerosis: Present and future. Yanaba K J Dermatol; 2016 Jan; 43(1):46-55. PubMed ID: 26782006 [TBL] [Abstract][Full Text] [Related]
5. Scleroderma in Children and Adolescents: Localized Scleroderma and Systemic Sclerosis. Li SC Pediatr Clin North Am; 2018 Aug; 65(4):757-781. PubMed ID: 30031497 [TBL] [Abstract][Full Text] [Related]
6. Treating skin and lung fibrosis in systemic sclerosis: a future filled with promise? Antic M; Distler JH; Distler O Curr Opin Pharmacol; 2013 Jun; 13(3):455-62. PubMed ID: 23747024 [TBL] [Abstract][Full Text] [Related]
7. Systemic sclerosis and localized scleroderma--current concepts and novel targets for therapy. Distler O; Cozzio A Semin Immunopathol; 2016 Jan; 38(1):87-95. PubMed ID: 26577237 [TBL] [Abstract][Full Text] [Related]
8. A comprehensive framework for navigating patient care in systemic sclerosis: A global response to the need for improving the practice of diagnostic and preventive strategies in SSc. Saketkoo LA; Frech T; Varjú C; Domsic R; Farrell J; Gordon JK; Mihai C; Sandorfi N; Shapiro L; Poole J; Volkmann ER; Lammi M; McAnally K; Alexanderson H; Pettersson H; Hant F; Kuwana M; Shah AA; Smith V; Hsu V; Kowal-Bielecka O; Assassi S; Cutolo M; Kayser C; Shanmugam VK; Vonk MC; Fligelstone K; Baldwin N; Connolly K; Ronnow A; Toth B; Suave M; Farrington S; Bernstein EJ; Crofford LJ; Czirják L; Jensen K; Hinchclif M; Hudson M; Lammi MR; Mansour J; Morgan ND; Mendoza F; Nikpour M; Pauling J; Riemekasten G; Russell AM; Scholand MB; Seigart E; Rodriguez-Reyna TS; Hummers L; Walker U; Steen V Best Pract Res Clin Rheumatol; 2021 Sep; 35(3):101707. PubMed ID: 34538573 [TBL] [Abstract][Full Text] [Related]
9. Systemic and localized scleroderma in children: current and future treatment options. Rosenkranz ME; Agle LM; Efthimiou P; Lehman TJ Paediatr Drugs; 2006; 8(2):85-97. PubMed ID: 16608370 [TBL] [Abstract][Full Text] [Related]
10. The contemporary management of systemic sclerosis. Eldoma M; Pope J Expert Rev Clin Immunol; 2018 Jul; 14(7):573-582. PubMed ID: 29874475 [TBL] [Abstract][Full Text] [Related]
14. Recent advances in the diagnosis and treatment of systemic sclerosis. Kowal-Bielecka O; Bielecki M; Kowal K Pol Arch Med Wewn; 2013; 123(1-2):51-8. PubMed ID: 23344666 [TBL] [Abstract][Full Text] [Related]
15. Use of Extracorporeal Photopheresis in Scleroderma: A Review. Du AX; Osman M; Gniadecki R Dermatology; 2020; 236(2):105-110. PubMed ID: 31362294 [TBL] [Abstract][Full Text] [Related]
16. Current treatment options in systemic Sclerosis (Scleroderma). Stummvoll GH Acta Med Austriaca; 2002; 29(1):14-9. PubMed ID: 11899748 [TBL] [Abstract][Full Text] [Related]
17. Recent Advances in Treatment of Systemic Sclerosis and Morphea. Teske N; Fett N Am J Clin Dermatol; 2024 Mar; 25(2):213-226. PubMed ID: 38087156 [TBL] [Abstract][Full Text] [Related]
18. Assessment of kidney involvement in systemic sclerosis: From scleroderma renal crisis to subclinical renal vasculopathy. Gigante A; Leodori G; Pellicano C; Villa A; Rosato E Am J Med Sci; 2022 Nov; 364(5):529-537. PubMed ID: 35537505 [TBL] [Abstract][Full Text] [Related]
19. [Systemic sclerosis and scleroderma circumscripta--disturbances of selected serum parameters which are responsible for vascular changes and CD34 expression in involved skin]. Dziankowska-Bartkowiak B; Zebrowska A; Wagrowska-Danielewicz M; Kobos J; Waszczykowska E Przegl Lek; 2009; 66(12):1040-5. PubMed ID: 20514902 [TBL] [Abstract][Full Text] [Related]